Credit: K KStock/Adobe stock
Medicaid spending on GLP-1 receptor agonists has skyrocketed over the past five years. Just in the past 12 months, Medicaid spending on GLP-1s specifically for obesity has reached more than $3.5 billion, according to an analysis by Real Chemistry.
A combination of increased usage and expanded state coverage is driving Medicaid spending up exponentially, reaching more than $500 million per month as of October.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
